Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoMET: Metformin with TEC in Neoadjuvant Breast Cancer
NCT01929811Phase 2Terminated
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Oct 2013
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of liquid metformin (Aspargo Labs) in breast cancer (2 arms), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Pathologic Complete Response Rate at 5 months. Started Oct 2013; status: terminated.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01929811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01929811.